Clinical efficacy and safety of Vitaros /Virirec (Alprostadil cream) for the treatment of erectile dysfunction

Size: px
Start display at page:

Download "Clinical efficacy and safety of Vitaros /Virirec (Alprostadil cream) for the treatment of erectile dysfunction"

Transcription

1 Urologia 2015 ; 82 ( 2): DOI: /uro UISSN DRUG REVIEW Clinical efficacy and safety of Vitaros /Virirec (Alprostadil cream) for the treatment of erectile dysfunction Ignacio Moncada 1, Béatrice Cuzin 2 1 Hospital La Zarzuela c/pléyades, Madrid - Spain 2 Department of Urology and Transplantation, Universitary E Herriot Hospital, Lyon Cedex - France ABSTRACT Erectile dysfunction (ED) is a very common disorder with a deep impact on patients and their partners. Several options are now available for treating ED; oral pharmacotherapy with phosphodiesterase-5 (PDE5) inhibitors currently represents the first-line option for many ED patients. Vitaros /Virirec is new topical, non-invasive treatment for ED that offers the combination of an active drug (alprostadil, a synthetic PGE1) with a skin enhancer that improves its local absorption directly at the site of action. Vitaros /Virirec has a favorable pharmacodynamic profile and is poorly absorbed in systemic circulation. This makes it suitable in any circumstances and results in a reduced risk of adverse events (AEs), being systemic AEs reported in only 3% of the treated population. Its clinical efficacy has been demonstrated in both phase II and III trials, showing a global efficacy up to 83% with the 300 μg dose in patients with severe ED significantly better than placebo. Its fast onset of action together with its favorable toxicity profile and lack of interactions with other drugs makes Vitaros /Virirec a first-line therapeutic option for patients with ED, particularly for individuals who are reluctant to take systemic treatments or with AEs. It may also have an important role in patients not responding to PDE5 inhibitors, particularly those with ED after radical prostatectomy. Keywords: Alprostadil, Erectile dysfunction, Topic application, Vitaros /Virirec Introduction Erectile dysfunction (ED) can be defined as the consistent inability to obtain and maintain an adequate penile erection sufficient for a satisfactory sexual activity (1). It is a common disorder, with increasing incidence in men over 40 years of age. The prevalence of ED has been estimated to be between 2 and 10% in men aged between 40 and 50 years, 30 and 40% in men years, and more than 50% in men over the age of 70 (2-4). Due to the increase in healthy aging population, ED is becoming a serious health problem. Apart from pathophysiological implications of the disorder, several pathologies are also associated with ED [cardiovascular (CV) disease, diabetes, prostatectomy], further increasing the proportion of individuals affected. ED strongly contributes to an unsatisfactory sexual life and, as a consequence, the quality of life of both affected men and their partners is also greatly impaired (5). Accepted: February 11, 2015 Published online: March 3, 2015 Corresponding author: Ignacio Moncada, MD Hospital La Zarzuela c/pléyades, Aravaca Madrid, Spain ignacio@moncada.name Treatment of ED has been shown to have a positive effect on the quality of life and overall satisfaction for both patients and their partners (6). The guidelines of the European Association of Urology recommend psychosexual counseling and phosphodiesterase-5 (PDE5) inhibitors as first-line treatment for ED (5). However, this class of drugs is associated with treatment failure in 11-44% of patients depending on the patient population under study (7). In addition, PDE5 inhibitors have several pharmacological interactions for which they are contraindicated, such as patients taking nitrates. Also, PDE5 inhibitors have numerous side effects that can cause treatment discontinuation, particularly headache, visual disturbances, muscular pain, and dyspepsia (8). Local treatment modalities (intracavernosal injection therapy, intraurethral alprostadil, vacuum erection devices) have been used as an alternative or in combination with PDE5 inhibitors. Herein, we present the pharmacology, clinical efficacy data, and safety profile of Vitaros /Virirec, a new alprostadil cream formulated with a novel skin permeation enhancing drug delivery system. Molecular mechanism and pathophysiology of erectile dysfunction Penile erection is mostly governed by the tone of the penis smooth muscle (which represents roughly half of the volume of the corpus cavernosum) through its control of different hemodynamic events (9). Proper levels of agonists and 2015 The Authors. This article is published by Wichtig Publishing and licensed under Creative Commons Attribution-NC-ND 4.0 International (CC BY-NC-ND 4.0). Any commercial use is not permitted and is subject to Publisher s permissions. Full information is available at

2 Moncada and Cuzin 85 receptors, calcium homeostasis as well as proper contacts between smooth muscle cells are key factors in controlling contractility. A concerted action of these factors is necessary to ensure penile erection and, in turn, any functional abnormality can lead to ED (1, 9). Nitric oxide (NO) represents the primary neurotransmitter involved in penile erection. Relaxation of arteriolar and cavernosal smooth muscle induced by NO produces dilation of arteries/arterioles, resulting in increased blood flow into the corporal sinuses, causing the cavernosal sinuses to expand while trapping arterial inflow and compressing subtunical small veins. This process called veno-occlusive mechanism impedes return of venous blood and maintains erection. In general, the relaxation of cavernosal smooth muscles can be considered as a kind of reset of the contractile machinery. In this context, a decrease in intracellular Ca ++ concentrations is needed, which depends on the accumulation of the intracellular second messengers camp and cgmp and activation of ion channels. The general cascade leading to penile erection can be summarized as follows: following appropriate stimuli, there is neural and endothelial release of NO, entering the smooth muscle cell, activation of guanylatecyclase that catalyzes the conversion of GTP to cgmp thus lowering cytosolic Ca ++ levels and triggering relaxation. A parallel pathway is activated by prostaglandins such as PGE1, which stimulate adenylatecyclase through the interaction with G protein coupled receptors (GPCRs), which in turn induces an increase in camp. An additional, important role is played by intracellular communications mostly mediated by connexins, which are gap junction proteins. Connexins ensure a sort of continuity between adjacent cells and allow the flow of ions and second messengers (1, 9). ED can be classified as a psychogenic disorder, as an organic disorder (with neurogenic, hormonal, arterial, or drugrelated causes), and, as is most frequent, a combination of both organic and psychogenic factors (1). Several risk factors are implicated in the development of ED. In particular, a relation between ED and CV risk has been reported, and known CV risk factors such as hypertension, diabetes mellitus, dyslipidemia are also important risk factors for ED (1, 10). In addition, as persistence of ED has been shown to correlate with a subsequent cardiac event, persistent ED can be seen as a predictive sign of the occurrence of a CV event. From a mechanistic point of view, ED and CV diseases have been shown to have some common pathophysiological pathways. Other risk factors for the development of ED are metabolic syndrome, hypogonadism, obesity, other genitourinary diseases (prostatectomy for any reason), as well as depression, anxiety, stress, anger, sedentary life, and smoking habits. ED has an important negative psychological impact and affects the relationships with partner, family, and friends, thus resulting in a reduced quality of life. These negative effects, however, can be overcome by effective therapy, as demonstrated in several studies (1). ED treatment Correct management of ED is important considering that responders to treatment report a significantly better quality of life and general health status. There are several therapeutic options for ED, and it is important to define the etiology of ED to treat the causes rather than the symptoms. For example, in case of ED associated with hormonal dysfunction, specific treatment of the hormonal defect can potentially cure ED. Another important consideration is the identification of lifestyleassociated risk factors, which, if modified, can ameliorate ED. Nonetheless, the majority of ED patients are treated with options that are not specific to the cause. Given the mechanisms at the basis of defects in penile erection, first-line systemic therapy involves the use of PDE5 inhibitors (11-13). These drugs act by inhibiting the ability of PDE5 to hydrolyze cgmp to increase blood flow in the arterioles, inducing smooth muscle relaxation and penile erection. They do not work as erection initiators, as they require sexual stimulation to facilitate erection. There are four selective inhibitors of PDE5 that are approved by both the EMA and FDA for ED: sildenafil tadalafil, avanafil, and vardenafil. These drugs have a variable peak of efficacy as well as differences in duration of action. They have all been demonstrated to be efficacious in a large proportion of patients during chronic treatment (1, 14). The response rate depends on the drug used and the patient s characteristics; overall, a response rate of around 70% is generally achieved after weeks of treatment (13). These drugs are normally on-demand and only tadalafil has been approved for daily dosing. For the majority of patients, the on-demand therapy is a preferred option in general. Several factors may limit the use of systemic administration of PDE5 inhibitors (13, 15). First, a high-fat meal reduces the efficacy of short-acting PDE5 inhibitors, possibly due to decreased absorption (16). Interactions with other drugs have been reported that preclude the use of PDE5 inhibitors (8, 16). For example, in patients under treatment with nitrates, the concomitant use of PDE5 inhibitors can cause unpredictable decreases in blood pressure, and they are thus contraindicated in combination with nitrates. Additive adverse events (AEs) have been reported with the concomitant use of antihypertensive drugs or alpha blockers. Interaction with drugs inhibiting P450 pathway, and in particular CYP3A4, which metabolizes PDE5 inhibitors, is well characterized. The use of drugs known to inhibit this specific isoform (such as ketoconazole, erythromycin, clarithromycin) can increase the circulating levels of PDE5 inhibitors, and thus dose reduction is required. On the contrary, for drugs known to induce CYP3A4 (such as phenobarbital, carbamazepine, and phenytoin), a dose increase is required to counteract the increased metabolic breakdown. Lastly, these drugs are associated with a number of common AEs such as headache, visual disturbances, flushing, dyspepsia, and muscular and back pain or nasal congestion, with frequencies that vary depending on the individual drug (1). An alternative option is the use of intracavernous injections, provided that healthy vasculature is present. Several drugs can be employed including papaverine and alprostadil, while the latter is most widely used. This treatment modality is highly efficacious with a rapid effect on penile erection and a dose-dependent duration (17). Although this treatment has proven efficacy, its use is limited by the high rate of discontinuations, mostly due to the treatment modality (including fear of penile puncture). Nowadays, intracavernous injection can be offered as second-line treatment in patients

3 86 Alprostadil cream for erectile dysfunction not responding to systemic therapy. Alprostadil can also be administered intraurethrally through the use of a specific device that has been approved for the use in patients with ED. In this formulation, the drug is inserted in a pellet, directly in the urethra where it diffuses via vascular absorption to the corpora cavernosa. However, this therapeutic modality is considered less effective than intracavernous injection (17). Furthermore, together with the aforementioned contraindications for intracavernous administration, intraurethral treatment can also induce urethral pain and bleeding. There is thus a need for a new therapeutic paradigm that is able to offer reliable efficacy, satisfaction, increased compliance, and better tolerance. A new formulation of alprostadil cream: Vitaros /Virirec Alprostadil cream (Vitaros /Virirec ) combines the efficacy of a well known drug (alprostadil) with an easy to use formulation that does not involve the use of systemic drugs or more invasive topical applications, which has the characteristics to meet all the above-mentioned needs for treatment of ED (17, 18). Alprostadil is a synthetic analog of prostaglandin E1, equivalent to naturally occurring PGE1. Its mechanism of action involves the binding to G protein coupled PGE1 receptors localized on the surface of smooth muscle cells, thus activating camp, which in turn induces penile vascular smooth muscle relaxation to provide penile erection. In contrast to PDE5 inhibitors, which require an erectogenic stimulus to activate the NO/guanylatecyclase pathway, alprostadil acts independently of the psychological and neurological components of the entire process leading to erection, thanks to its action as a direct agonist (17-19) (Fig. 1). Vitaros /Virirec is available in a cream formulation, which ensures a rapid absorption of the drug at the site of action. In fact, this specific formulation contains, together with alprostadil, an enhancer, namely DDAIP.HCl (an ester of N- dimethylalanine and dodecanol), which temporarily loosens tight junctions present in skin epithelial cells, as a result of its interaction with the polar region of the phospholipid bilayer on the plasma membrane (18, 20) (Fig. 2). By increasing the motion of lipid hydrocarbon chains and intercalating within the skin ceramides, it improves the diffusion of alprostadil through the skin. Vitaros /Virirec is applied in drops directly to the meatus of the glans penis, allowing for quick penetration of the drug, directly at the site of action. Vitaros /Virirec has a favorable pharmacodynamic profile. Through the use of laser Doppler meter, it has been reported that the microcirculation of the glans improved rapidly after topical administration, reaching the levels observed in a physiologically normal erection. Within min, full rigidity of the penis is achieved, which lasts for more than 1 h (18). The fast, rapid, and reliable erectile response provided by Vitaros /Virirec has been recently demonstrated in phase III trials, in which it has been shown that the majority of patients (N = 434) receiving alprostadil topical cream 300 μg had a time interval (from administration) to successful penetration attempts of 5-30 min (Fig. 3). In addition, approximately 98% of the administered dose of Vitaros /Virirec Fig. 1 - Mechanism of action of Vitaros /Virirec. Schematic mechanism of penile erection with a focus on second messengers: cgmp and camp. Alprostadil directly binds to G-protein coupled PGE1 receptors on the smooth muscle cell surface and activates the camp pathway resulting in relaxation of penile vascular smooth muscle and penile erection. Although PDE5 inhibitors require previous activation of the NO/guanylatecyclase pathway by erectogenic stimuli, alprostadil is a direct agonist that acts independently of the psychological and neurological components of the erection process. cgmp, cyclic guanosine monophosphate; camp, cyclic adenosine monophosphate; NO, nitric oxide. is retained in the fossa navicularis of the penis, thus minimizing systemic diffusion of the drug (18, 21). Pharmacokinetic studies, performed measuring not only PGE1 but also its metabolites PGEo and 15-keto-PGEo as well as DDAIP, confirmed the data on absorption, with levels that are so low that they preclude the determination of pharmacokinetic parameters. The maximum plasma levels of the metabolite 15-keto-PGEo are detected within 1 h following application (17). Taken together, these data indicate that, with this formulation, alprostadil is not systemically adsorbed to a significant extent and that it is rapidly metabolized, thereby predicting low or absent systemic toxicity. There are no known drug interactions between Vitaros / Virirec and other medications and there are no special warnings or precautions for drug drug interactions, food, or alcohol. The lack of interference with food and alcohol is an advantage for the cream formulation, as it eliminates the need to coordinate the timing of meals around sexual activity, in contrast to PDE5 inhibitors whose efficacy, with the exception of tadalafil, is reduced by heavy and fatty meals due to prolonged absorption (16).

4 Moncada and Cuzin 87 Fig. 2 - Mechanism of action of the skin permeation enhancer DDAIP. HCl (ester of N-dimethylalanine and dodecanol). camp, cyclic adenosine monophosphate; NO, nitric oxide. Modified from (17). Fig. 3 - Onset of action of Vitaros / Virirec. The data presented are from two multicenter, placebo-controlled, double-blind, parallel-group phase III studies conducted on a large cohort of 1732 patients (mean age 60 years) with moderate to severe ED and concomitant medical conditions. Patients were randomly assigned to receive placebo or alprostadil topical cream in doses of 100, 200, or 300 μg for 12 weeks. The number of patients is shown for each time interval considering time from administration to successful penetration attempts for the 300 μg dose. Clinical efficacy of Vitaros /Virirec The efficacy and safety of Vitaros /Virirec has been studied in two phase II studies in patients with mild to moderate (N = 161) and severe (N = 142) ED (22). The primary efficacy parameter was changed from baseline to final visit (after 10 drug doses in a 6-week period) in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF). Secondary efficacy parameters included change from baseline to final visit in the other domains of the IIEF and in the overall IIEF score, successful vaginal penetrations based on Sexual Encounter Profile (SEP), the Patient Self-Assessment of Erection (PSAE), and Global Assessment Questionnaire (GAQ) scores. In patients with severe ED, the changes in EF domain score and total IIEF scores from baseline were significantly higher in the 300 μg Vitaros /Virirec treatment

5 88 Alprostadil cream for erectile dysfunction Fig. 4 - Changes in erectile function domain score from baseline to final visit (+-SD) in controls ( ) and Vitaros /Virirec -treated patients ( ); *p<0.01; IIEF-EF, International Index of Erectile Function, domain Erectile Function. Adapted from (22). Fig. 6 - Last square mean change from baseline to endpoint in primary efficacy parameters in controls (n = 411) ( ) and patients treated with 300 μg Vitaros /Virirec (N = 410) ( ). IIEF-EF, International Index of Erectile Function, domain Erectile Function; SEP2 vaginal penetration/attempt rate; SEP3 intercourse completion to ejaculation rate. *p<0.001; Least square difference relative to placebo by ANOVA. Fig. 5 - Percentage of patients reporting improvement (GAQ) (p<0.001). Adapted from (22). group than the placebo group (p<0.01; Fig. 4). These changes were clinically meaningful. The successful vaginal penetration rate (SEP-Q3/Q1) was increased in the 300 μg treatment group compared with placebo (38.6 vs. 15.6), although this difference did not reach statistical significance. However, 83% of patients with severe ED receiving 300 μg Vitaros /Virirec reported a significant improvement in erections (GAQ) compared with 26% in the placebo group (p<0.001; Fig. 5). It is noteworthy that, due to the non-restrictive inclusion criteria in the study, about 61% of patients suffered from CV disease and 49% had diabetes. A meta-analysis of the earlier two phase II, multicenter, double-blind, dose-ranging studies involving a total of 303 patients with ED confirmed the efficacy of Vitaros /Virirec topical cream (23). The efficacy of Vitaros /Virirec has also been confirmed in two multicenter, randomized, placebo-controlled, parallel-group, double-blind, phase III trials enrolling a total of 1732 patients with moderate to severe ED (mean baseline IIEF-EF 13.7) and a wide range of concomitant medical conditions and treatments (22% had diabetes, 32% had CV disease, 12% had underwent prostatectomy, 47% were hypertensive, and 16% were being treated with nitrates and alpha-blockers) (24). In these studies, ED patients were randomly assigned to receive placebo or Vitaros /Virirec at 100, 200, or 300 μg for 24 single doses over a 12-week period. The efficacy measures were changes in EF domain of the IIEF, vaginal penetration/attempt rate (SEP question 2), and intercourse completion to ejaculation rate (SEP question 3) between baseline and final visit. In addition, at the end of treatment, the percentage of patients reporting improvements in erection was assessed by the GAQ. The results corroborated the phase II results with a significant improvement in all efficacy parameters in Vitaros /Virirec -treated patients compared with placebo (Fig. 6). Moreover, the percentage of patients reporting improved erections during the 12 weeks of treatment was 52% in the 300 μg Vitaros / Virirec treated group vs. 20% in the placebo arm (p<0.001). However, the reported magnitude of the effect was lower than previously reported. Possible explanations for this discrepancy include the fact that the study included patients with different comorbidities/treatments and a mean patient age of about 60 years (37% were >65 years of age). A number of post-hoc analyses of the phase III clinical data were performed by stratifying patients with different levels of disease severity and comorbidities. Patients were divided into five categories according to medical history: cardiac, diabetes, prostatectomy, sildenafil failure, and hypertension. In addition, each category could be divided into subcategories: mild, moderate, and severe according to baseline ED severity; changes in the IIEF-EF, SEP-Q2 (penetration success), SEP-Q3 (maintenance success), IIEF-EF final 26 (normalization of EF), and GAQ scores were analyzed. Interestingly, a high percentage of clinically significant improvements were observed in patients in the 300 µg group with comorbid cardiac disease or hypertension. Figure 7

6 Moncada and Cuzin 89 Fig. 7 - Percentage of patients with changes in IIEF-EF scores in the placebo ( ) and Vitaros /Virirec ( ) groups with cardiac history, diabetes, prostatectomy, and hypertension (panel A); percentage of patients with a positive GAQ response in the control ( ) and Vitaros / Virirec ( ) groups (p< vs. placebo) (panel B). Fig. 8 - Long-term efficacy at 6 months. shows the percentage of patients with clinically significant changes in the IIEF-EF (panel A) and in GAQ scores (panel B) in subgroups with different medical history. Clinically significant improvements were seen in all three ED subcategories with 50, 40, and 22% of patients, respectively, with mild, moderate, and severe ED showing a clinically relevant change in the IIEF-EF score (25). In patients with sildenafil failure and in those who previously used sildenafil, a consistent overall improvement in EF was observed, regardless of ED severity (26). The potential efficacy of Vitaros /Virirec in patients failing previous ED treatments is also documented by the data from a survey in which 152 patients with ED were interviewed. In that study, 53% of patients who had previously tried at least two different ED treatment modalities reported that Vitaros /Virirec was efficacious. These data strongly support the efficacy of Vitaros /Virirec in patients with different degrees of ED, in patients with a range of comorbidities, and in patients failing sildenafil therapy. The efficacy of long-term treatment with Vitaros /Virirec was evaluated in a multicenter, open-label study in which the drug was administered during an initial 4-week period at the 200 μg dosage, and then adjusted to 100, 200, or 300 μg according to patient responsiveness for up to 9 months (two doses/week) (27). The majority of patients (75%) chose 300 μg Vitaros /Virirec as the final dose with a dosing frequency of one application every 4-7 days. ED improvement, based on changes in the IIEF-EF score, was significant for the 300 μg group (p<0.001), (Fig. 8) with an overall improvement of ED from severe to moderate before treatment to moderate to mild after treatment. In addition, in the group of patients treated with 300 μg Vitaros /Virirec,

7 90 Alprostadil cream for erectile dysfunction there was a large increase in the percentage of patients giving affirmative responses in both the SEP Q2 and SEP Q3; by the end of the study, 80.3 and 61.1% of patients, respectively, gave an affirmative response (27). Safety and tolerability of Vitaros /Virirec Alprostadil topical cream (Vitaros /Virirec ) and the skin permeation enhancer DDAIP.HCl have been evaluated in several dose toxicity, irritation, and genotoxicity animal studies and shown to be devoid of genotoxic potential. In addition, topical administration of DDAIP.HCl does not induce local or systemic toxicity or tumorigenicity. The available clinical data suggest that Vitaros /Virirec is safe and generally well tolerated. Indeed, in the overall phase II program, the vast majority (97%) of Vitaros / Virirec -related side effects were of mild or moderate in severity and short duration (<60 min) (22). Nearly, all these AEs were localized at the application site (i.e., genital pain, tenderness, and erythema). Approximately 2% of AEs were partner-related, and the majority of cases were related to mild, short-lasting ( 60 min post-intercourse) vaginal burning. Hypotension was uncommon and half of the reported cases were asymptomatic. No cases of prolonged erections were reported. The safety data from phase III studies substantiated the spectrum of AEs reported in phase II studies (24), with no treatment-related serious AEs. The most frequent AEs occurred locally at the site of application and resolved within 2 h; only 2.7% of patients withdrew from these studies because of treatment-related AEs. Tables I and II show the summary of the most common systemic and local treatment-related AEs after Vitaros /Virirec administration reported by patients and their partners. In patients, the most frequently reported AEs were urogenital reactions (application site reactions such as penile burning, 23% or erythema, 11.3%, genital pain, 17.5 %, and penis disorder, 3.5%), while those most frequently reported by partners were vulvovaginal disorders (burning or vaginitis), 6.5% (24). Several of the urogenital AEs reported were of lower frequency than those with transurethral or suppository alprostadil administration (28). The safety data on the long-term use of Vitaros /Virirec also suggest that this formulation is safe and well tolerated (27). Indeed, at the time of study closure, a total of 787 patients had been involved in the study for a wide range of time frame ( days) and most of the reported AEs were mild in intensity, transient (<24 h), short-lasting, and reversible; AEs leading to discontinuation were seen in less than 5% of cases. Importantly, no CV AEs were observed with long-term use (29). It is noteworthy that over 85% of patients participating in this long-term study had already used Vitaros /Virirec in phase III studies, which suggests that they did not perceive a tolerance issue with long-term use. Vitaros /Virirec topical cream has been used in clinical studies concomitantly with other drugs (steroidal and non-steroidal analgesics, anti-inflammatory drugs, anti-hypertensive drugs, diuretics, anti-hyperglycemic agents including insulin, anti-lipidemic drugs, multivitamins, and thyroid medication) and no apparent interference with its efficacy or safety has been reported, further supporting the favorable safety profile of this formulation (22-24). TABLE I - Most common systemic adverse events following treatment with Vitaros /Virirec 300 μg Systemic side effects Placebo (n = 434) Vitaros 300 µg (n = 434) Patient n (%) Total 3 (0.6) 13 (3.0) Headache 1 (0.2) - Dizziness 1 (0.2) 5 (1.1) Hyperesthesia 0 (0) 6 (1.4) Rash 1 (0.2) 2 (0.5) Adapted from (24). TABLE II - Most common local (urogenital) adverse events in ed patients and partners after treatment with Vitaros /Virirec 300 μg Local side effects Patient n (%) Placebo (n = 434) Vitaros 300 µg (n = 434) Total 51 (10.6) 279 (64.9) Balanitis 3 (0.7) 20 (4.6) Edema penile 1 (0.2) 6 (1.4) Fullness genital - 4 (0.9) Genital pain 2 (0.5) 76 (17.5) Penile burning 26 (0.6) 100 (23) Penile erythema 9 (2.1) 49 (11.3) Penile itching 1 (0.2) 5 (1.2) Penile tingling 7 (1.6) 4 (0.9) Penis disorder 2 (0.4) 15 (3.5) Partner n (%) Total 13 (3) 28 (6.5) Vaginal burning 8 (1.8) 19 (4.4.) Vaginitis 5 (1.2) 9 (2.1) Adapted from (24). Concluding remarks Sexual health is considered to be a reflection of general health: male sexual dysfunction has a negative impact of quality of life of the patients and their partners. ED is the main sexual dysfunction affecting men of all age groups. Recent epidemiological data suggest that not only it is still underdiagnosed and undertreated but also men who suffer from ED are unsatisfied with their relationship, their physician, and with the available treatments. Although current therapy for ED most frequently consists of systemic treatment with a PDE5 inhibitor, this does not always reflect patient preference. Indeed, in a recent survey involving 152 patients with ED in which individuals were asked to express

8 Moncada and Cuzin 91 Fig. 9 - Panel A: Ranking of patient preferences (first to fourth choice) of the ideal route of administration for therapy of ED. Survey of 152 patients with ED who were asked to rank their preferred route of administration therapy for ED. Panel B: Schematic representation of therapeutic choices in patients with ED. their preference for ED therapy according to the route of administration (systemic/oral medications, topical therapy/ topical creams, injectable, and intra-urethral therapies), more than half selected a topical cream as the first choice (53%) (Fig. 9A). In addition, although men taking a PDE5 inhibitor for ED have been reported to be extremely or very satisfied with sildenafil, tadalafil, and vardenafil, respectively, in 35, 47, and 44% of cases (30), about one half of patients show some level of treatment dissatisfaction (31, 32). In addition, it has been reported that the average use of PDE5 inhibitors was less than once per week, supporting the evidence that on-demand use may better fit both men s and couples needs compared with chronic use. This would suggest that topical treatment in ED represents a valid therapeutic approach, preferred by patients as first choice of treatment, and should be offered by physicians to patients with different severities of ED (Fig. 9B). In summary, Vitaros /Virirec can be considered a valid therapeutic option in any type of patient affected by ED. This new formulation of alprostadil cream combined with a novel skin permeation enhancing drug delivery system allows fast onset of action, with reliable efficacy in any circumstances, and no interference with food or alcohol consumption. It can be safely administered in men undergoing therapy for several comorbidities (α-blockers and antihypertensive drugs) and, more importantly, it is devoid of serious systemic AEs. Phase II and III clinical studies have documented its efficacy in improving EF. Vitaros /Virirec is safe and well tolerated. Most treatment-related side effects are mild or moderate in severity and of short duration (22), and nearly all AEs are localized at the application site (i.e., genital pain, tenderness, and erythema). Due to its favorable pharmacological properties, Vitaros /Virirec is indicated for all ED patients including those not responding to PDE5 inhibitors, and in whom PDE5 inhibitors are contraindicated or not tolerated. It is also suitable in patients who are reluctant to take pills for any reason, in patients with CV risk, and with CV comorbidity treated with nitrates. Thus, Vitaros /Virirec is a therapeutic option in ED, from mild to severe, that can fit patient s needs and expectations. Disclosures Financial support: Editorial assistance for the publication of this manuscript was provided by HPS Health Publishing & Services Srl. Milan, Italy. This assistance was funded by Recordati S.p.A. Conflicts of interest: BC: Astellas, Auxilium, Lilly, Majorelle, Menarini and Pierre Fabre; IM: Advisor for Recordati, Menarini, SOBI and Lilly. References 1. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013; 381(9861): Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the Cologne Male Survey. Int J Impot Res. 2000;12(6): Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med. 2010;7(4 Pt 2): Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med. 2009;6(9): Hatzimouratidis K, Amar E, Eardley I, et al; European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5): Latini DM, Penson DF, Lubeck DP, Wallace KL, Henning JM, Lue TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. J Urol. 2003;169(4): Carvalheira AA, Pereira NM, Maroco J, Forjaz V. Dropout in the treatment of erectile dysfunction with PDE5: a study on

9 92 Alprostadil cream for erectile dysfunction predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012;9(9): Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation. 2010;122(1): Saenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2000;12(s4) (Suppl 4):S34-S Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol. 2006;50(4): Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am. 2007;36(2): Konstantinos G, Petros P. Phosphodiesterase-5 inhibitors: future perspectives. Curr Pharm Des. 2009;15(30): Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010; 7(11): Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24): Park NC, Kim TN, Park HJ. Treatment Strategy for non-responders to PDE5 inhibitors. World J Mens Health. 2013;31(1): Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007;19(3): Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15(3): Becher E. Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2004;5(3): Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009;6(8): Wolka AM, Rytting JH, Reed BL, Finnin BC. The interaction of the penetration enhancer DDAIP with a phospholipid model membrane. Int J Pharm. 2004;271(1-2): Yeager J, Beihn RM. Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. Int J Impot Res. 2005;17(1): Padma-Nathan H, Steidle C, Salem S, Tayse N, Yeager J, Harning R. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res. 2003;15(1): Steidle C, Padma-Nathan H, Salem S, et al. Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. Urology. 2002;60(6): Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006;68(2): Buvat J, Damaj B, Fernando Y, et al. Significant improvement of erectile function Following treatment with alprostadile cream (Vitaros) in 1651 patients with erectile dysfunction. ESSM. Amsterdam; Mulhall J, Buvat J, Goldstein I, Damaj B, Frank D, Fernando Y. Vitaros efficacy and safety in viagra non-responders with longer term use. J Urol. 2013;189(4):e Rooney M, Pfister W, Mahoney M, Nelson M, Yeager J, Steidle C. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med. 2009;6(2): Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents. J Manag Care Pharm. 2005;11(2): Mulhall J, Porst H, Goldstein I, et al. Comparison of vitaros efficacy and safety with short-term and longer term use. J Sex Med. 2013;10: Jannini EA, Sternbach N, Limoncin E, et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J Sex Med. 2014;11(1): Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S; EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). Eur Urol. 2007;51(2): , discussion Travison TG, Hall SA, Fisher WA, et al. Correlates of PDE5i use among subjects with erectile dysfunction in two populationbased surveys. J Sex Med. 2011;8(11):

IC351 (tadalafil, Cialis): update on clinical experience

IC351 (tadalafil, Cialis): update on clinical experience (2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,

More information

Erectile Dysfunction: A Primer for Primary Care Providers

Erectile Dysfunction: A Primer for Primary Care Providers Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand

More information

Erectile Dysfunction Medical Treatment

Erectile Dysfunction Medical Treatment 1 Erectile Dysfunction Medical Treatment Alireza Ghoreifi Assistant of Urology Mashhad University of Medical Sciences March 2012 2 Treatment of ED Unknown cases of ED First-line therapy Second-line therapy

More information

A NEW APPROACH FOR THE PATIENT WITH ERECTILE DYSFUNCTION

A NEW APPROACH FOR THE PATIENT WITH ERECTILE DYSFUNCTION Promotional supplement A NEW APPROACH FOR THE PATIENT WITH ERECTILE DYSFUNCTION This symposium took place on 21 st March 2015 (18.00 19.30) as part of the Annual European Association of Urology (EAU) Congress

More information

MALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara

MALE SEXUAL DYSFUNCTION. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara MALE SEXUAL DYSFUNCTION Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara DEFINITION The inability to achieve a satisfactory sexual relationship May involve : - inadequacy

More information

Evidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction

Evidence Review for Surrey Prescribing Clinical Network. Treatment: Oral and non-oral combination therapy for erectile dysfunction Evidence Review for Surrey Prescribing Clinical Network Treatment: Oral and non-oral combination therapy for erectile dysfunction Prepared by: Linda Honey Topic Submitted by: Prescribing Clinical Network

More information

GUIDELINES ON ERECTILE DYSFUNCTION

GUIDELINES ON ERECTILE DYSFUNCTION 16 GUIDELINES ON ERECTILE DYSFUNCTION E. Wespes (chairman), E. Amar, D. Hatzichristou, Dr. F. Montorsi, J. Pryor, Y. Vardi Eur Urol 2002;41:1-5 1. Background, definition and classification Male erectile

More information

GUIDELINES ON ERECTILE DYSFUNCTION

GUIDELINES ON ERECTILE DYSFUNCTION GUIDELINES ON ERECTILE DYSFUNCTION (Text updated March 2005) E. Wespes (chairman), E. Amar, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi, J. Pryor, Y. Vardi 88 Erectile Dysfunction Eur Urol 2001;40:97-101

More information

for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology

for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly

More information

Managing Erectile Dysfunction

Managing Erectile Dysfunction Managing Erectile Dysfunction Lewis E. Harpster MD, FACS Urology of Central PA 4/23/16 1 Objectives 1. Review physiologic mechanism of erection 2. Discuss medical management of ED 3. Discuss surgical management

More information

, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001

, David Stultz, MD. Erectile Dysfunction. David Stultz, MD September 10, 2001 Erectile Dysfunction David Stultz, MD September 10, 2001 Case Presentation A 66 year old male presents to your office requesting Viagra. He states that for the past year he has had difficulty forming

More information

Managing the Patient with Erectile Dysfunction: What Would You Do?

Managing the Patient with Erectile Dysfunction: What Would You Do? Managing the Patient with Erectile Dysfunction: What Would You Do? Florida A & M University College of Pharmacy and Pharmaceutical Sciences 42 nd Annual Clinical Symposium Wayne A. Sampson, M.D. Cross

More information

About Erectile Dysfunction. Causes, self-test and treatment

About Erectile Dysfunction. Causes, self-test and treatment About Erectile Dysfunction Causes, self-test and treatment 2015 One Way S.r.l. All rights reserved. Gift copy for physicians. Illustrated by Davide Ceccon With an unrestricted grant from Recordati About

More information

Erectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid

Erectile dysfunction. By Anas Hindawi Supervised by Dr Khalid AL Sayyid Erectile dysfunction By Anas Hindawi Supervised by Dr Khalid AL Sayyid ED is the persistent/recurrent inability to attain and/or maintain a penile erection rigid enough for satisfactory sexual intercourse

More information

Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction

Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Canadian Undergraduate Urology Curriculum (CanUUC): Erectile Dysfunction Last reviewed July 2014 Objectives 1. Define erectile dysfunction 2. List and classify the risk factors for erectile dysfunction

More information

ERECTILE DYSFUNCTION DIAGNOSIS

ERECTILE DYSFUNCTION DIAGNOSIS ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz

More information

Testosterone and PDE5 inhibitors in the aging male

Testosterone and PDE5 inhibitors in the aging male Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005

More information

New Medicine Assessment

New Medicine Assessment New Medicine Assessment Alprostadil 3 milligram/gram cream (Vitaros ) Treatment of men 18 years of age with erectile dysfunction Recommendation: Alprostadil 3 mg/g cream is recommended as an alternative

More information

Medical Management of Erectile Dysfunction. Maarten Albersen MD PhD University Hospitals Leuven,

Medical Management of Erectile Dysfunction. Maarten Albersen MD PhD University Hospitals Leuven, Medical Management of Erectile Dysfunction Maarten Albersen MD PhD University Hospitals Leuven, Belgium @maartenalbersen COI Consultancy/speaker for: Ferring, Sanofi, BSCI, Coloplast, Pfizer, Lilly, Menarini,

More information

/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY

/02/ /0 Vol. 168, , October 2002 THE JOURNAL OF UROLOGY 0022-5347/02/1684-1332/0 Vol. 168, 1332 1336, October 2002 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2002 by AMERICAN UROLOGICAL ASSOCIATION, INC. DOI: 10.1097/01.ju.0000028041.27703.da Original

More information

avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL.

avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL. avanafil 50mg, 100mg, 200mg tablets (Spedra ) SMC No. (980/14) A. Menarini Farmaceutica Internazionale SRL. 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

Jan Farrell. Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT

Jan Farrell. Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT Jan Farrell Nurse Consultant Urology Department of Urology Rotherham General Hospital NHS FT Aims of session To promote discussion / interaction Opportunity to discuss with peers Promote learning / share

More information

Erectile Dysfunction; It s Not Just About Sex

Erectile Dysfunction; It s Not Just About Sex Erectile Dysfunction; It s Not Just About Sex Disclosures Conflict of interest: I am not paid by Boston Scientific but once in a while they buy me a tasty meal. I do routinely use their products without

More information

Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT

Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT Jan Farrell Nurse Consultant Urological Services Department of Urology Rotherham General Hospital NHS FT Aims of session To promote discussion / interaction Opportunity to discuss with peers Promote learning

More information

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established

More information

Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation

Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation www.kjurology.org DOI:.4/kju.2.5.3.22 Sexual Dysfunction/Infertility Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation Jang Ho Bae, Phil Hyun Song, Hyun Tae Kim, Ki Hak

More information

ED treatments: PDE5 inhibitors, injections and vacuum devices

ED treatments: PDE5 inhibitors, injections and vacuum devices ED treatments: PDE5 inhibitors, injections and vacuum devices Martin Steggall Clinical Nurse Specialist (Erectile Dysfunction and Premature Ejaculation) Barts Health NHS Trust; Associate Dean, Director

More information

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY

/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY 0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7

More information

Erectile dysfunction: unmet needs

Erectile dysfunction: unmet needs Erectile dysfunction: unmet needs Dimitris Hatzichristou Professor of Urology / Andrology Director, Center for Sexual and Reproductive Health Aristotle University of Thessaloniki, Greece The numbers MMAS

More information

I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E

I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E 2 0 1 6 DESPITE THE COMMON COMPLAINT, EACH PATIENT COMES AS AN INDIVIDUAL, WITH UNIQUE EXPECTATIONS My special interest Counseling patients

More information

Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders

Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders DOI: 10.1111/j.1745-7262.2007.00227.x www.asiaandro.com. Clinical Experience. Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders Shih-Tsung

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

ORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction

ORIGINAL INVESTIGATION. Sildenafil for Male Erectile Dysfunction Sildenafil for Male Erectile Dysfunction A Systematic Review and Meta-analysis ORIGINAL INVESTIGATION Howard A. Fink, MD, MPH; Roderick Mac Donald, MS; Indulis R. Rutks, BS; David B. Nelson, PhD; Timothy

More information

Dipartimento Ostetricia, Ginecologia, Urologia - Clinica Urologica Università di Napoli Federico II, Italy; 2

Dipartimento Ostetricia, Ginecologia, Urologia - Clinica Urologica Università di Napoli Federico II, Italy; 2 ORIGINAL PAPER DOI: 10.4081/aiua.2016.2.128 A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil

More information

Opinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation?

Opinion: Yes. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Difference of opinion Vol. 43 (3): 385-389, May - June, 2017 doi: 10.1590/S1677-5538.IBJU.2017.03.03 PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? Opinion:

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation

GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update March 2009) E. Wespes, E. Amar, I. Eardley, F. Giuliano, D. Hatzichristou, K. Hatzimouratidis, F. Montorsi,

More information

Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer

Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Daily vs. on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) February 2018

More information

Diagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist

Diagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia

More information

ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204)

ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION. Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) ERECTION MISDIRECTION: PENILE REHABILITATION & TREATMENTS FOR ERECTILE DYSFUNCTION Gregory Harochaw Pharmacy Manager Tache Pharmacy (204) 233-3469 Nerve Function After careful prostatectomy where the erectile

More information

Clinical Trial Study Synopsis

Clinical Trial Study Synopsis Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency

More information

Up to 85 Percent of Men Achieved Significantly Improved Erections

Up to 85 Percent of Men Achieved Significantly Improved Erections Corporate Investor Relations First Release of Vardenafil Phase III Pivotal Study Data: Up to 85 Percent of Men Achieved Significantly Improved Erections Additional Phase III Data Show Significant Improvement

More information

Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction

Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction (2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of

More information

Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several

Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several Defined as the consistent inability to attain and maintain an erection adequate for sexual intercourse Usually qualified by being present for several months and occurring at least half the time. Vinik

More information

Erectile Dysfunction Prior Authorization with Quantity Limit Criteria Program Summary

Erectile Dysfunction Prior Authorization with Quantity Limit Criteria Program Summary Prior Authorization with Quantity Limit Criteria Program Summary Objective The intent of the prior authorization (PA) program for (ED) is to ensure appropriate selection of patients for treatment according

More information

Erectile Dysfunction Case Study 2. Medical Student Case-Based Learning

Erectile Dysfunction Case Study 2. Medical Student Case-Based Learning Erectile Dysfunction Case Study 2 Medical Student Case-Based Learning The Case of Mr. Power s Limp Mojo Mr. Powers develops erectile dysfunction after his radical prostatectomy for prostate cancer. You

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2012 Review date: September 2014 Bulletin 169: Daily Tadalafil (Cialis ) for penile rehabilitation following radical prostactectomy JPC Recommendation:

More information

Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology

Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) A Second Generation Technology Y. Reisman, MD, PhD. 1, A. Hind, MD. 2, A. Varaneckas, MD. 3, I. Motil, MD. 4 1 Men's Health

More information

Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis

Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis (2003) 15, 318 322 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction

More information

/03/ /0 Vol. 170, , July 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION

/03/ /0 Vol. 170, , July 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION 0022-5347/03/1701-0159/0 Vol. 170, 159 163, July 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000072524.82345.6d COMPARISON OF SATISFACTION

More information

The efficacy and safety of tadalafil: an update

The efficacy and safety of tadalafil: an update Original Article C.C. CARSON et al. The efficacy and safety of tadalafil: an update C.C. CARSON, J. RAJFER, I. EARDLEY, S. CARRIER, J.S. DENNE, D.J. WALKER, W. SHEN and W.H. CORDELL Department of Surgery,

More information

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction

A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction A Proposed Study of Hyperbaric Oxygen Therapy Following Radical Prostatectomy: Effects on Erectile Dysfunction Anthony J. Bella MD, FRCSC Division of Urology, Department of Surgery and Department of Neuroscience

More information

Update on Erection Dysfunction. Seacourses Eastern Caribbean December 30, 2017 January 6, 2018 Stacy Elliott MD

Update on Erection Dysfunction. Seacourses Eastern Caribbean December 30, 2017 January 6, 2018 Stacy Elliott MD Update on Erection Dysfunction Seacourses Eastern Caribbean December 30, 2017 January 6, 2018 Stacy Elliott MD Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced,

More information

Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution

Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution Advances in Urology Volume 2009, Article ID 852437, 4 pages doi:10.1155/2009/852437 Review Article Penile Rehabilitation Therapy with PDE-V Inhibitors Following Radical Prostatectomy: Proceed with Caution

More information

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust

Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter

More information

Clinic for urology, pediatric urology and andrology. Penile diseases. Dr. Arne Hauptmann

Clinic for urology, pediatric urology and andrology. Penile diseases. Dr. Arne Hauptmann Clinic for urology, pediatric urology and andrology JUSTUS- LIEBIG UNVERISTY GIESSEN Penile diseases Dr. Arne Hauptmann Clinic for urology, pediatric urology and andrology University Giessen und Marburg

More information

Sexual dysfunction in men with diabetes

Sexual dysfunction in men with diabetes Article Sexual dysfunction in men with diabetes Lesley Mills Citation: Mills L (2015) Sexual dysfunction in men with diabetes. Journal of Diabetes Nursing 19: 332 8 Article points 1. Sexual dysfunction

More information

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction

Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Robert C. Eyre, MD, FACS Associate Clinical Professor of Surgery (Urology) Harvard Medical School Post-prostatectomy Incontinence

More information

Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016

Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016 Erectile Dysfunction (ED) Shawn McGee M.D. CentraCare Adult and Pediatric Urology January 30 th, 2016 Erectile dysfunction: The inability to attain or maintain penile erection sufficient for satisfactory

More information

EAU GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation

EAU GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation EAU GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Partial text update March 2015) K. Hatzimouratidis (Chair), F. Giuliano, I. Moncada, A. Muneer, A. Salonia (Vice-chair),

More information

LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP

LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO

More information

Psychopharmacological Treatment of Sexual Dysfunction. American Society Clinical Psychopharmacology

Psychopharmacological Treatment of Sexual Dysfunction. American Society Clinical Psychopharmacology Psychopharmacological Treatment of Sexual Dysfunction American Society Clinical Psychopharmacology 2005 Teaching Points 1. Sexual dysfunction is highly prevalent in the general population 2. Sexual dysfunction

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction

A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction 625408TAU0010.1177/1756287215625408Therapeutic Advances in UrologyMC Cho and J Paick research-article2016 Therapeutic Advances in Urology Review A review of the efficacy and safety of mirodenafil in the

More information

Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology

Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology Sidney Glina Faculdade de Medicina do ABC Instituto H. Ellis Editor-in-Chief of the International Brazilian Journal of Urology (www.intbrazjurol.com.br) glinas@terra.com.br Conflict of Interest: In the

More information

Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on Sex Hormones Levels

Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on Sex Hormones Levels Australian Journal of Basic and Applied Sciences, 2(3): 779-784, 2008 ISSN 1991-8178 Chronic Daily Administration of Vardenafil in Erectile Dysfunction Patients Has No Impact on Semen Parameters or on

More information

Gerald Brock Professor of Surgery University of Western Ontario

Gerald Brock Professor of Surgery University of Western Ontario Treatment Induced Erectile Dysfunction Gerald Brock Professor of Surgery University of Western Ontario 1 1 2 Should you believe in Rehab? 3 3 Should you believe in Rehab? Avoidance Education related to

More information

MANAGEMENT UPDATE , LLC MedReviews

MANAGEMENT UPDATE , LLC MedReviews MANAGEMENT UPDATE 2013 MedReviews, LLC rostate cancer is the most common cancer in men over the age of 50 years. 1 When patients undergo a radical prostatectomy (RP), there is a risk of postoperative erectile

More information

SEXUAL HEALTH. Erectile Dysfunction

SEXUAL HEALTH. Erectile Dysfunction SEXUAL HEALTH Erectile Dysfunction Don t Let Erectile Dysfunction Keep You from a Satisfying Sex Life. What Is Erectile Dysfunction or ED? Who Gets ED? Men who have ED have a problem getting or keeping

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VIAGRA 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg sildenafil as citrate.

More information

Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study

Initial experience with linear focused shockwave treatment for erectile dysfunction: a 6-month follow-up pilot study International Journal of Impotence Research (2014), 1 5 2014 Macmillan Publishers Limited All rights reserved 0955-9930/14 www.nature.com/ijir ORIGINAL ARTICLE Initial experience with linear focused shockwave

More information

Erectile dysfunction (ED) is a common male sexual. Clinical Guidelines

Erectile dysfunction (ED) is a common male sexual. Clinical Guidelines Clinical Guidelines Annals of Internal Medicine Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis Alexander Tsertsvadze, MD, MSc;

More information

Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary

Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary Phosphodiesterase Type 5 Inhibitors Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-4,23 Agent FDA Approved Dosage and Administration Indication Cialis (tadalafil) (ED) ED; As needed:

More information

Tadalafil: a novel treatment for erectile dysfunction

Tadalafil: a novel treatment for erectile dysfunction European Heart Journal Supplements (22) 4 (Supplement H), H24 H31 Tadalafil: a novel treatment for erectile dysfunction F. Giuliano 1 and L. Varanese 2 1 Department of Urology, AP-HP, Centre Hospitalier

More information

Treatment for ED. Education and couple assessment. Lifestyle advice. Patient Information. Page 1 / 10. Patient Information - Treatment for ED

Treatment for ED. Education and couple assessment. Lifestyle advice. Patient Information. Page 1 / 10. Patient Information - Treatment for ED Patient Information English 3 Treatment for ED The underlined terms are listed in the glossary. Erectile dysfunction (ED) is a common condition. Although it is not life threatening, it can negatively affect

More information

Medicines Q&As. Date prepared: November 2016

Medicines Q&As. Date prepared: November 2016 Q&A 128.3 What is the rationale and evidence for the use of phosphodiesterase-5 inhibitors as supportive therapy to rehabilitate Erectile Function after nerve sparing radical prostatectomy? Summary Prepared

More information

Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties

Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties 466282TAU511756287212466282Therapeutic Advances in UrologyGT Kedia, S Ückert 2012 Therapeutic Advances in Urology Review Avanafil for the treatment of erectile dysfunction: initial data and clinical key

More information

Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil

Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil Sexual Medicine RECOVERY OF ERECTILE FUNCTION AFTER NERVE-SPARING RP WITH NIGHTLY LOW-DOSE SILDENAFIL BANNOWSKY et al. Associate Editor Michael G. Wyllie Editorial Board Ian Eardley, UK Jean Fourcroy,

More information

The effect of sildenafil on electrostimulation-induced erection in the rat model

The effect of sildenafil on electrostimulation-induced erection in the rat model (2002) 14, 251 255 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The effect of sildenafil on electrostimulation-induced erection in the rat model N Ueno 1,

More information

Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction

Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University

More information

A review of phosphodiesterase type 5 inhibitors

A review of phosphodiesterase type 5 inhibitors A review of phosphodiesterase type 5 inhibitors Abstract Schellack N, BCur, BPharm, PhD(Pharmacy), Senior Lecturer Agoro A, BPharm, Academic Intern Department of Pharmacy, Faculty of Health Sciences, University

More information

ERECTILE DYSFUNCTION TREATMENTS

ERECTILE DYSFUNCTION TREATMENTS ERECTILE DYSFUNCTION TREATMENTS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

ERECTILE DYSFUNCTION. Prof. Khan Abul Kalam Azad. Head, Department of Medicine, Dhaka Medical College President, Bangladesh Society of Medicine

ERECTILE DYSFUNCTION. Prof. Khan Abul Kalam Azad. Head, Department of Medicine, Dhaka Medical College President, Bangladesh Society of Medicine ERECTILE DYSFUNCTION Prof. Khan Abul Kalam Azad Head, Department of Medicine, Dhaka Medical College President, Bangladesh Society of Medicine Bangladesh Society of Medicine Department of Medicine Dhaka

More information

Disclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION

Disclosure Slide. Dr Michael Gillman IMPOTENCE ERECTILE DIFFICULTIES. Do Men Really Care??? 15/10/2014 ASSESSMENT OF ERECTILE DYSFUNCTION ASSESSMENT OF ERECTILE DYSFUNCTION Dr Michael Gillman St Andrews Hospital North St Specialist Suites Mater Hospital 3 rd Floor Mater Private Clinic Wesley Hospital Suite 5 Level 9 Evan Thomson Bld Cleveland-

More information

Topical application of a Rho-kinase inhibitor in rats causes penile erection

Topical application of a Rho-kinase inhibitor in rats causes penile erection (2004) 16, 294 298 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Topical application of a Rho-kinase inhibitor in rats causes penile erection Y Dai 1,2,3, K

More information

MODULE 4: ERECTILE DYSFUNCTION

MODULE 4: ERECTILE DYSFUNCTION MODULE 4: ERECTILE DYSFUNCTION KEYWORDS: Erectile dysfunction, phosphodiesterase inhibitors, sexual dysfunction LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to: 1.

More information

aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB

aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB aviptadil / phentolamine 25 micrograms / 2mg solution for injection (Invicorp ) SMC No 1284/17 Evolan Pharma AB 10 November 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i

Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i Schemi terapeutici complessi per la gestione della disfunzione erettile post trattamento del carcinoma prostatico: non solo PDE5i M. Lazzeri MD-PhD Department of Urology Ist. Clinico Humanitas IRCCS Schema

More information

Erectile Dysfunction An overview. Lorraine Montgomery Specialist Nurse Practitioner Urology

Erectile Dysfunction An overview. Lorraine Montgomery Specialist Nurse Practitioner Urology Erectile Dysfunction An overview Lorraine Montgomery Specialist Nurse Practitioner Urology BAUN Essential Urology Study Day Centre for life: Newcastle. 20/9/2017 What is erectile dysfunction? The persistent

More information

Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China

Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Original Article Penile rehabilitation after radical prostatectomy: patients attitude and feasibility in China Yi-Jun Shen 1,2, Jian Li 1,2, Ding-Wei Ye 1,2 1 Department of Urology, Fudan University Shanghai

More information

An Update on Pharmacological Treatment of Erectile Dysfunction

An Update on Pharmacological Treatment of Erectile Dysfunction An Update on Pharmacological Treatment of Erectile Dysfunction a report by Konstantinos Hatzimouratidis and Dimitrios G Hatzichristou Lecturer in Urology, and Associate Professor in Urology/Andrology and

More information

Shockwave Therapy Applications

Shockwave Therapy Applications Shockwave Pressure Level (bar) Shockwave Therapy Applications 500 Urology 250 0 ESWL ~ 450 Bar Stone Fragmentation ESWT ~ 200 bar Anti Inflammatory Orthopedics LSWT ~80 bar Angiogenesis ED 80 s 90 s 2000+

More information

Indications Rebound pulmonary hypertension caused by withdrawal of Nitric Oxide in paediatric patients on PICU (unlicensed indication).

Indications Rebound pulmonary hypertension caused by withdrawal of Nitric Oxide in paediatric patients on PICU (unlicensed indication). Medicines Management & Pharmacy Services (MMPS) Guidelines on the use of sildenafil (Revatio) in acute pulmonary hypertension for paediatric cardiac patients Indications Rebound pulmonary hypertension

More information

Erectile dysfunction (ED) is one of the most

Erectile dysfunction (ED) is one of the most Low-Intensity Extracorporeal Shock Wave Therapy A Novel Effective Treatment for Erectile Dysfunction in Severe ED Patients Who Respond Poorly to PDE5 Inhibitor Therapyjsm_2498 1..6 1 Ilan Gruenwald, MD,

More information

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents FORMULARY MANAGEMENT Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents HELEN ELOISE CAMPBELL, BS, PharmD ABSTRACT BACKGROUND: Significant advances in the pharmacologic treatment

More information

Treatment for ED. Education and couple assessment. Lifestyle advice. Patient Information. Page 1 / 9. Patient Information - Treatment for ED

Treatment for ED. Education and couple assessment. Lifestyle advice. Patient Information. Page 1 / 9. Patient Information - Treatment for ED Patient Information English 3 Treatment for ED The underlined terms are listed in the glossary. Erectile dysfunction (ED) is a common condition. Although it is not life threatening, it can negatively affect

More information

With My Heart, Can or Should I Take Erectile Dysfunction Drugs?

With My Heart, Can or Should I Take Erectile Dysfunction Drugs? With My Heart, Can or Should I Take Erectile Dysfunction Drugs? Timothy R. Malinowski MD, FACC UMG Carolina Cardiology Consultants Greenville Health System Definition of Erectile Dysfunction 1992 NIH Consensus

More information

Sexual problems in the ageing male: ED

Sexual problems in the ageing male: ED Sexual problems in the ageing male: ED Prism IV September 25-26 Bruges, Belgium Dr. HHJ Leliefeld and Prof. FMJ Debruyne, urologists The Netherlands Erectile disfunction Definition & Prevalence The erectile

More information

ERECTILE DYSFUNCTION. & Current Therapies. GP Conference, Rotorua 7-10 June 2012

ERECTILE DYSFUNCTION. & Current Therapies. GP Conference, Rotorua 7-10 June 2012 ERECTILE DYSFUNCTION & Current Therapies GP Conference, Rotorua 7-10 June 2012 Jan Burns & Annie Woodsford Jan: EN, RCpN, BHSc, RPN (USA),MHSc, Member of the Sexual Medicine Society Urology Nurse Specialist

More information